Lilly REGARDs ramu GI data positively but may need to wait for RAINBOW's end
This article was originally published in Scrip
Executive Summary
Eli Lilly's anti-VEGF monoclonal antibody ramucirumab provided an overall survival (OS) benefit of 1.4 months and a progression-free survival (PFS) benefit of 0.8 months for patients with metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma in the Phase III REGARD clinical trial.